AstraZeneca is in discussions to take over US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group, according to unnamed sources cited by the Financial Times, which first reported the talks on 3 August 2026 The Guardian.

Talks between the two companies have been held in recent months, but there is no certainty that a deal will be concluded. AstraZeneca is run by Pascal Soriot, its longtime chief executive, under whose leadership the company's share price has more than quadrupled. During that period AstraZeneca overtook UK rival GSK in size and rebuilt its drug pipeline around cancer immunotherapies, drugs that harness the body's immune system to fight tumours.

A combined entity would rank as the world's fourth-largest drugmaker by market value and would stand as one of the biggest-ever pharmaceutical deals. AstraZeneca, headquartered in Cambridge, was the second-biggest listed company in the UK with a market value of nearly £196bn before news of the BMS talks broke. Bristol Myers Squibb, headquartered in Princeton, is worth $133bn and is known for its cancer treatments.

AstraZeneca's FTSE 100-listed shares plunged more than 7% to a low of £116.46 in early trading in London as investors reacted to the news. The sell-off came just a week after AstraZeneca said it was confident of hitting its growth targets for 2030, expecting to achieve $80bn (£60bn) in annual sales, up from $59bn the previous year. A few days after that statement, BMS beat Wall Street expectations with its second-quarter results and lifted its 2026 outlook.

The timing of the talks also follows a clinical trial failure for AstraZeneca's leading heart disease drug in development, Wainua. That setback, set against the company's bullish 2030 guidance, frames the strategic tension at the heart of the potential deal: whether AstraZeneca can sustain its growth trajectory through its existing pipeline alone or whether it needs a transformative acquisition to close the gap.

Chris Beauchamp, a chief market analyst at investment platform IG, noted that AstraZeneca had recently said it did not need M&A to hit its targets. He also flagged the pair's large cancer divisions as a major hurdle to a successful deal, since overlapping oncology portfolios would likely draw intense antitrust scrutiny from regulators on both sides of the Atlantic.

Bristol Myers Squibb has its own history of large-scale dealmaking. In 2019, it completed its $74bn acquisition of Celgene after clearing US Federal Trade Commission requirements, having cited $2.5bn in cost synergies BMS Press Release, 2019. It has also pursued smaller targeted acquisitions, including Turning Point Therapeutics, a San Diego-based clinical-stage biopharmaceutical company. That track record suggests BMS is no stranger to integration, though the scale of a combination with AstraZeneca would dwarf its previous transactions.

AstraZeneca itself was formed in 1999 from the merger of the Swedish company Astra AB and the UK company Zeneca Group, which had been spun off from Imperial Chemical Industries five years earlier. The company fended off a hostile bid from US rival Pfizer in 2014 that valued the company at almost £70bn. Under UK takeover rules at the time, Pfizer and AstraZeneca could resume merger discussions after a three-month cooling-off period if AstraZeneca initiated them The Guardian, 2014. That episode has lingered as a defining moment in AstraZeneca's modern corporate identity, with Soriot having successfully argued that independence would deliver greater value for shareholders.

The company's deepening US footprint is a critical backdrop. AstraZeneca is already investing $50bn in research and manufacturing in the US by 2030, and in June it completed a direct listing of its shares on the New York Stock Exchange. A BMS acquisition would accelerate that transatlantic shift, potentially raising questions about AstraZeneca's corporate domicile and its identity as a UK-listed champion.

The Telegraph reported on 2 August 2026 that AstraZeneca was plotting the $400bn (£300bn) merger, noting the deal would likely raise fresh questions over the company The Telegraph.

Looking at what this means for the competitive landscape, a combined AstraZeneca-BMS would consolidate two of oncology's most formidable franchises into a single entity. The overlap in cancer portfolios, which IG's Beauchamp identified as a major hurdle, is also where the strategic rationale is strongest. Both companies have built their pipelines around checkpoint inhibitors and targeted therapies. Merging would eliminate a competitor in certain oncology segments while expanding combined capabilities in others. Regulators in Washington and Brussels will be the ultimate arbiters of whether that consolidation is acceptable.

The share price reaction, while sharp, reflects investor wariness of execution risk in mega-mergers rather than outright rejection of the strategic logic. AstraZeneca's premium valuation, built on Soriot's track record of pipeline delivery, gives it meaningful currency for a stock-based transaction. But paying that premium for a company with overlapping franchises risks diluting the very pipeline strength that underpins the acquirer's valuation.

Whether the talks progress beyond their current stage will depend on bridging the gap between AstraZeneca's confidence in its standalone trajectory and the transformative appeal of combining with a US peer whose own quarterly results have just exceeded expectations.